Trial · NCT01038128

An Open Label Trial of Memantine in the Treatment of Bulimia Nervosa and Body Dysmorphic Disorder

NCT01038128, Not applicable, Completed, Mclean Hospital; results first posted 2012-06-12

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. An Open Label Trial of Memantine in the Treatment of Bulimia Nervosa and Body Dysmorphic Disorder. Trials, record NCT01038128. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01038128

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: An Open Label Trial of Memantine in the Treatment of Bulimia Nervosa and Body Dysmorphic Disorder
NCT number: NCT01038128
Status: Completed
Phases: Not applicable
Enrollment: 5 participants, actual
Lead sponsor: Mclean Hospital
Conditions: Bulimia Nervosa, Body Dysmorphic Disorder
Interventions: Memantine
First posted: 2009-12-23
Last updated: 2015-05-04
Results first posted: 2012-06-12

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Binge Eating and Self-induced Vomiting Episodes	Baseline to 12 weeks	Number of self-reported binge eating and self-induced vomiting episodes during the week prior to the Baseline and Endpoint Visits.
Primary	Ratings of Eating Pathology	Baseline to 12 weeks	Ratings obtained from the self-induced vomiting and laxative misuse sections of the Eating Disorder Examination. The scale asks participants to calculate discreet episodes of self-induced vomiting and laxative misuses over the period of four weeks. Generally, the value obtained is the number of occurrences. However, in cases where the number of occurrences was too great to be calculated, the number "777" was used. The scale is therefore open-ended, with higher numbers coinciding with a greater number of episodes.
Primary	Clinical Global Impression Scale	Baseline to 12 weeks	Disorder severity is measured based on the Clinical Global Impression Scale. The scale ranges from 1 unit (Not at all ill) to 7 units (extremely ill).
Primary	Body Dysmorphic Disorder Version of the Yale Brown Obsessive Compulsive Scale	Baseline to 12 weeks	The scale ranges from 0 to 91 units, with 0 representing the least ill and 91 representing the most ill.
Primary	Brown Assessments of Belief Scale	Baseline to 12 weeks	The range for this scale is 0 to 28 units, with 0 representing the least ill and 28 representing the most ill.

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Binge Eating and Self-induced Vomiting Episodes	Baseline to 12 weeks	One subject completed. The remaining two subjects' last observation was carried forward.	number of episodes	MEAN
PRIMARY	Ratings of Eating Pathology	Baseline to 12 weeks	One subject completed. The remaining two subjects' last observation was carried forward.	units on a scale	MEAN
PRIMARY	Clinical Global Impression Scale	Baseline to 12 weeks	One subject completed. The remaining two subjects' last observation was carried forward.	units on a scale	MEAN
PRIMARY	Body Dysmorphic Disorder Version of the Yale Brown Obsessive Compulsive Scale	Baseline to 12 weeks	One subject completed. The remaining two subjects' last observation was carried forward.	units on a scale	MEAN
PRIMARY	Brown Assessments of Belief Scale	Baseline to 12 weeks	This scale was only administered to participants with Body Dysmorphic Disorder. No participants with BDD completed the Baseline Visit and, therefore, no results were available to analyze.

Source ClinicalTrials.gov

Results by group10

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Number of Binge Eating and Self-induced Vomiting Episodes	Memantine	Binge Eating Baseline	20.67	Standard Deviation 14.74	number of episodes
Number of Binge Eating and Self-induced Vomiting Episodes	Memantine	Binge Eating Endpoint	31.33	Standard Deviation 35.25	number of episodes
Number of Binge Eating and Self-induced Vomiting Episodes	Memantine	Purging Baseline	21.67	Standard Deviation 27.30	number of episodes
Number of Binge Eating and Self-induced Vomiting Episodes	Memantine	Purging Endpoint	36.67	Standard Deviation 54.93	number of episodes
Ratings of Eating Pathology	Memantine	Baseline Data	101.33	Standard Deviation 71.07	units on a scale
Ratings of Eating Pathology	Memantine	Endpoint Data	38.67	Standard Deviation 30.27	units on a scale
Clinical Global Impression Scale	Memantine	Baseline Data	5	Standard Deviation 0	units on a scale
Clinical Global Impression Scale	Memantine	Endpoint Data	4	Standard Deviation 1.41	units on a scale
Body Dysmorphic Disorder Version of the Yale Brown Obsessive Compulsive Scale	Memantine	Baseline Data	57.67	Standard Deviation 0.58	units on a scale
Body Dysmorphic Disorder Version of the Yale Brown Obsessive Compulsive Scale	Memantine	Endpoint Data	48.67	Standard Deviation 6.51	units on a scale

Source ClinicalTrials.gov

Participant flow4

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Memantine	5
Overall Study	Baseline Visit	Memantine	3
Overall Study	COMPLETED	Memantine	1
Overall Study	NOT COMPLETED	Memantine	4

Source ClinicalTrials.gov

Adverse events6

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Constipation	Gastrointestinal disorders	Memantine	1	3	1
other	Headache	General disorders	Memantine	1	3	1
other	Pain when closing eyes	Eye disorders	Memantine	1	3	1
other	Constant eye pressure	Eye disorders	Memantine	1	3	1
other	Eye pain	Eye disorders	Memantine	1	3	1
other	Cough	Respiratory, thoracic and mediastinal disorders	Memantine	1	3	1

Source ClinicalTrials.gov

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Memantine
Total, other adverse events	Memantine	3	3
Total, serious adverse events	Memantine	0	3

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01038128

GET https://conductscience.org/api/trials/v1/NCT01038128/registered

API reference For AI assistants